Diese Webseite verwendet Cookies. Mehr Infos
info@PortalDerWirtschaft.de | 02635/9224-11
mit Content-Marketing - Ihre News
Taros Chemicals GmbH & Co. KG |

Taros: 20,000 unprecedented chemical compounds delivered to the European Lead Factory Drug Discovery Platform

Bewerten Sie hier diesen Artikel:
1 Bewertung (Durchschnitt: 5)

Taros Chemicals, a privately owned CRO focused on serving the needs of pharmaceutical, chemical, agrochemical and biotech companies, announced that it achieved in November this year the benchmark of delivery of 20,000 unprecedented chemical compounds to b

Taros Chemicals, a leading European custom research and manufacturing organization announced it is robustly progressing through year 3 of the 5 year’s ELF project duration.

With over 20,000 compounds delivered into the Joint European Compound Library by end 2015, Taros is currently leading the SME contribution of novel screening compounds to the ELF collection. Starting from an initial monthly production of 100 compounds at the beginning of 2014, today more than 1,000 quality checked and purified compounds are made available for shipment every month.

 A distinctive characteristic of the Taros’ screening compounds is its high level of structural complexity and three-dimensionality, two features that are regarded as attractive in drug discovery application. Taros Chemicals takes the challenge to design and synthesized unprecedented spiro, bridge and fused polycycles with different degrees of saturation, conjugation and substitution patterns. The over 25 finalized scaffolds with high three-dimensional character provide versatile starting points and ample opportunities for further chemical exploration and growth during the hit-to-lead phase.


A recent joint publication authored by Taros scientists called "Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective" earlier this month in “Drug Discovery Today” details the results of a benchmark study performed on the screening compound collection being currently designed and synthesised within the Chemistry Consortium of European Lead Factory Consortium led by Taros.


Free download available until Dec. 25th, 2015: [Article]




About Taros Chemicals

Taros, an independent and privately owned contract research company based in Dortmund, Germany, has been serving the needs of pharmaceutical, chemical, agrochemical and biotech companies since 1999. More than 10.000 synthesis, research and process chemistry projects have successfully been delivered to the ever growing global customer base. Taros operates state-of-the art lab facilities and employs a team of scientists (65% of whom hold post-graduate degrees in Chemistry) who are committed to supporting the diverse needs of its customers in efficient drug discovery, medicinal chemistry and classical synthetic chemistry. Taros’ scientists combine more than 140 years industrial organic chemistry experience and over 60 years of active drug discovery experience from big pharmas and biotechs. They have expertise across a broad range of therapeutic areas (oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious) and in all small molecule target classes. Being committed to supporting our global customer base in efficient drug discovery, medicinal and synthetic chemistry initiatives, we have developed TarosGate®. TarosGate® is a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world. TarosGate® software is a major cornerstone for the efficient chemistry process management of the European Lead Factory drug development platform.

About the European Lead Factory

The European Lead Factory (ELF), initiated in January 2013, is a €196 million Public Private Partnership (PPP) supported by the Innovative Medicines Initiative (IMI) and is aimed at boosting the initial phases of the drug discovery process. Pharmaceutical companies, academic groups and five Discovery small and medium-sized enterprises (SMEs) have formed a pan-European consortisum to address the challenge of delivering an innovative, publicly-accessible, screening deck of synthetically-tractable compounds, named the Public Compound Collection (PCC). As part of the ELF, the seven participating pharmaceutical companies have contributed over 300,000 chemical compounds from their corporate chemical collections and the academic and SME members will deliver up to 200,000 compounds from unprecedented areas of biologically-relevant chemical space.

Für den Inhalt der Pressemitteilung ist der Einsteller, Youri R. Mesmoudi (Tel.: 0231 9742 72 11), verantwortlich.

Keywords: Taros Chemicals, Drug Discovery, Chemie, Wirkstoffforschung, Medizinalchemie, Youri Mesmoudi, Dimitrios Tzalis, Dortmund, European Lead Factory

Pressemitteilungstext: 570 Wörter, 4271 Zeichen. Pressemitteilung reklamieren

Unternehmensprofil: Taros Chemicals GmbH & Co. KG


Es wurde noch kein Kommentar zu diesem Thema abgegeben.

Ihr Kommentar zum Thema

Weitere Pressemitteilungen von Taros Chemicals GmbH & Co. KG lesen:

Taros Chemicals GmbH & Co. KG | 14.09.2017

Tackling unmet medical needs: Exciting new hits for a novel drug target involved in depression and pain unveiled in the EU Lead Factory

An exciting innovative target involved in these debilitating conditions was discovered by Dr Patrick McHugh, University of Huddersfield. “We don’t have the facilities to carry out large scale screening campaigns to fully assess the possibilities ...
Taros Chemicals GmbH & Co. KG | 19.10.2016

TV-Interview: euronews mit Business Planet besucht Taros Chemicals

Kleine und mittlere Unternehmen (KMU) sind das Rückgrat der europäischen Wirtschaft. Sie repräsentieren 99% aller Unternehmen in der EU. In den vergangenen fünf Jahren haben sie rund 85% der neuen Arbeitsplätze geschaffen und zwei Drittel der ge...
Taros Chemicals GmbH & Co. KG | 22.09.2015

Regenerative Medizin: Taros und Uni Köln wollen die Gewebezüchtung verbessern

Die Gewebezüchtung (tissue engineering) ist einer der zukünftig vielversprechendsten Therapieansätze in der modernen Medizin und birgt die Chance, Millionen von Menschen neue Heilungsmöglichkeiten zukommen zu lassen. Bisher etablierten Trägerp...